Ensign Peak Advisors
STOK icon

Ensign Peak Advisors’s Stoke Therapeutics STOK Stock Holding History

Ensign Peak Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-43,112
Closed -$553K – 2174
2022
Q3 		$553K Buy
43,112
+1,490
+4% +$23.7K ﹤0.01% 1401
2022
Q2 		$550K Buy
41,622
+40,432
+3,398% +$614K ﹤0.01% 1423
2022
Q1 		$25K Buy
+1,190
New +$23.8K ﹤0.01% 2167
2021
Q4 		– Sell
-1,294
Closed -$33K – 2238
2021
Q3 		$33K Hold
1,294
– – ﹤0.01% 1844
2021
Q2 		$44K Sell
1,294
-4,360
-77% -$154K ﹤0.01% 1815
2021
Q1 		$220K Sell
5,654
-873
-13% -$49.7K ﹤0.01% 1720
2020
Q4 		$404K Hold
6,527
– – ﹤0.01% 1641
2020
Q3 		$219K Buy
6,527
+2,441
+60% +$69.7K ﹤0.01% 1659
2020
Q2 		$97K Hold
4,086
– – ﹤0.01% 1631
2020
Q1 		$94K Sell
4,086
-4,987
-55% -$123K ﹤0.01% 1582
2019
Q4 		$256K Buy
+9,073
New +$228K ﹤0.01% 1606

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Ensign Peak Advisors's STOK Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Stoke Therapeutics (STOK) in Q4 2022, closing a stake of 43,112 shares — an estimated $553K sold.

Ensign Peak Advisors first reported a position in STOK in Q4 2019 and held it in 11 quarters. The position peaked at $553K in Q3 2022. 107 funds tracked by Wall St. Rank hold STOK as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Stoke Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 43,112 Stoke Therapeutics shares in Q4 2022, an estimated $553K.
  • Ensign Peak Advisors first reported a position in Stoke Therapeutics in Q4 2019 and held it in 11 quarters.
  • Ensign Peak Advisors's Stoke Therapeutics position peaked at $553K in Q3 2022.
  • 107 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.